This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).
This journal outlines best practices for engaging communities affected by chronic hepatitis B, emphasizing the importance of involving individuals with lived experiences in public health initiatives to improve diagnosis and treatment outcomes.
This journal evaluates the Oregon HOPE TeleHCV study, a peer-facilitated telemedicine model (Peer TeleHCV) for hepatitis C virus (HCV) treatment among people who use drugs (PWUD) in rural Oregon. The findings highlight high patient satisfaction and key factors that enhanced implementation, demonstrating the model’s potential to reduce barriers and improve treatment access.
This webpage explores the risks of untreated hepatitis C, highlighting its potential to cause severe liver damage, cirrhosis, liver failure, and even liver cancer. Beyond liver-related issues, the virus can also contribute to complications such as fatigue, joint pain, kidney disease, and diabetes. Early diagnosis and treatment are essential to preventing these long-term health risks and improving overall well-being.
This report outlines progress toward eliminating mother-to-child transmission of hepatitis B virus (HBV) in the Americas from 2012 to 2022. It highlights improvements in vaccination coverage, including birth doses, but also notes coverage declines in some countries, which could hinder elimination goals. The report emphasizes the need for maintaining high vaccination rates, expanding hepatitis B testing for pregnant women, and ensuring timely treatment for newborns.
This webpage discusses the impact of incorrect penicillin allergy labels on treatment delays for syphilis patients. It highlights how mislabeling a patient as allergic to penicillin can result in suboptimal treatments and prolonged infections.
This guideline outlines the Doxy-PEP Protocol for the prevention of certain sexually transmitted infections (STIs), specifically targeting syphilis, gonorrhea, and chlamydia, following potential exposure. It provides guidelines for healthcare providers on how to administer doxycycline as post-exposure prophylaxis (PEP), detailing protocols for prescription, timing, and patient education to reduce the risk of infection.
This article highlights groundbreaking research on tuberculosis (TB) treatment, revealing why a key TB drug remains effective against resistant strains. Rutgers Health researchers uncover the molecular mechanisms that enable this drug to combat TB bacteria, potentially inspiring improved treatments and drug development strategies. The findings emphasize the need for continued research to address antibiotic resistance and enhance global TB control efforts.
This journal investigates the prevalence of sexually transmitted infections (STIs) among women with vaginitis symptoms in a U.S. clinical study. Findings highlight the link between STIs and vaginal dysbiosis, emphasizing the need for comprehensive STI testing in this population.
This webpage highlights a recent study that reveals gaps in gonorrhea and chlamydia testing during pregnancy. It emphasizes the potential health risks these infections pose to both mother and child, urging the need for improved screening protocols. The study underscores the importance of regular prenatal testing to ensure better health outcomes for both.
